The gynecologic cancer program brings together experts to examine key updates and discuss how new data informs patient care. Below, review the agenda highlights and meet the co-chair guiding this year’s discussions.

Agenda Highlights

March 14, 4:25 PM
Front-Line Maintenance Therapy for Ovarian Cancer: It is a PARPi and Bevacizumab World – Don’t Fix What Is Not Broken vs We Can Do Better Than HRD – Opportunities for New Biomarkers and Agents to Improve Outcomes
March 15, 2:10 PM
Front-Line Metastatic Endometrial Cancer: Immunotherapy for All vs Molecular Profiling to Individualize Therapy – Immunotherapy Should Not Be an Empiric Selection
March 15, 4:25 PM
Treatment of Platinum-Sensitive and Resistant Recurrent Ovarian Cancer: Optimizing Outcomes with Currently Available Therapies – The Regulatory Standard Is the Treatment Standard vs Rethinking Recurrent Ovarian Cancer – ADCs, New Taxane Combinations, Bisp
Back to top